# Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma

> **NCT01506596** · PHASE2 · COMPLETED · sponsor: **Vector Oncology** · enrollment: 42 (actual)

## Conditions studied

- Liposarcoma
- Surgically Unresectable Liposarcoma
- Metastatic Liposarcoma

## Interventions

- **DRUG:** pazopanib

## Key facts

- **NCT ID:** NCT01506596
- **Lead sponsor:** Vector Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2014-10
- **Final completion:** 2016-03
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2017-02-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01506596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01506596, "Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01506596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*